425 results on '"Roghmann F"'
Search Results
2. Indikationen und Technik der Frühzystektomie
3. Breaking boundaries: Exploring extended pembrolizumab in first-line treatment of renal cell carcinoma with axitinib-pembrolizumab combination
4. First safety and efficacy results of the TAR-210 erdafitinib intravesical delivery system in patients with non–muscle-invasive bladder cancer with select FGFR alterations
5. Side effects of antibody-drug conjugates in the new era of tailored therapy in urologic malignancies
6. Results from the prospective randomized UroFollow trial comparing marker-guided vs. cystoscopy-based standard follow-up in patients with low/intermediate risk bladder cancer
7. The role of device-assisted therapies in the management of non-muscle invasive bladder cancer: A systematic review
8. Early recovery after surgery for radical cystectomy: comprehensive assessment and meta-analysis of existing protocols
9. EAU–ESMO consensus statements on the management of advanced and variant bladder cancer—an international collaborative multi-stakeholder effort: under the auspices of the EAU and ESMO Guidelines Committees
10. Modernes Netzwerken: Thematische Ausrichtungen in der Arbeitsgruppe „Blasenkarzinom Experimentell“ der GeSRU Academics
11. Is there evidence for a close connection between side of intravesical tumor location and ipsilateral lymphatic spread in lymph node-positive bladder cancer patients at radical cystectomy? Results of the PROMETRICS 2011 database
12. Impact of photodynamic diagnosis-assisted transurethral resection of bladder tumors on the prognostic outcome after radical cystectomy: results from PROMETRICS 2011
13. The effect of age at diagnosis on prostate cancer mortality: A grade-for-grade and stage-for-stage analysis
14. 1759P Enfortumab vedotin in metastatic urothelial carcinoma: Retrospective multicentre patient cohort
15. The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the “post-dissemination” period
16. Long-term survival in patients with germ cell testicular cancer: A population-based competing-risks regression analysis
17. Komplikationen in der frühen Rehabilitationsphase nach radikaler Zystektomie: Ein Vergleich zwischen Ileum Conduit und Neoblase
18. Versorgungsforschung zum Outcome von Patienten nach radikaler Zystektomie
19. Harnableitungspräferenz-Index (HARPI) als neues Instrument zur Unterstützung der Partizipativen Entscheidung bei der Wahl der Harnableitung
20. Die frühe longitudinale CRP-Kinetik sagt das Ansprechen gegenüber Anti-PD-(L)1-Immuncheckpoint-Blockade im metastasiertem Urothelkarzinom voraus
21. Die Expression des Enfortumab Vedotin Zielproteins Nectin-4 nimmt während der Metastasierung des Urothelkarzinoms stark ab
22. Prospektive Versorgungsforschung zum Outcome nach radikaler Zystektomie
23. Vorhersage der Tumorpersistenz in der Re-TUR-B durch den Xpert® Bladder Cancer Monitor - Ergebnisse einer prospektiven multizentrischen Studie (MoniTURB Trial)
24. Hodeninfarkt: Ungewöhnliche Komplikation der intravenösen Immunglobulintherapie bei multifokaler motorischer Neuropathie
25. Objektive Messung der lokalen Tumorlast bei Patienten mit Blasentumoren zur Pr��diktion des Tumorstadiums ��� wie messen wir am besten?
26. Enfortumab Vedotin bei metastasiertem Urothelkarzinom : retrospektive, multizentrische Patientenkohorte
27. EAU-ESMO consensus statements on the management of advanced and variant bladder cancer
28. Komplikationen nach Ileumconduitanlage: Harnableitungsspezifische Komplikationen nach radikaler Zystektomie
29. Klinische und histopathologische Parameter des Prostatakarzinoms: Einfluss anthropometrischer Indizes
30. Oncological and safety profiles in patients undergoing simultaneous transurethral resection of bladder tumor and prostate: Results from a large multicenter international collaboration
31. P121 - Selecting the best candidates for cisplatin-based adjuvant chemotherapy after radical cystectomy in patients with pN+ bladder cancer
32. A randomized, double-blind, placebo-controlled, phase 3 trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring susceptible FGFR3 genetic alterations: PROOF 302
33. Selecting the best candidates for cisplatin-based adjuvant chemotherapy after radical cystectomy in patients with pN+ bladder cancer
34. Selecting the best candidates for cisplatin-based adjuvant chemotherapy after radical cystectomy in pN+ bladder cancer patients
35. Vorhersage der Erkrankungsschwere von Patienten mit Fournier-Gangrän
36. Komplikationen nach radikaler Zystektomie in der frühen Rehabilitationsphase: Ein Vergleich zwischen Ileumconduit und orthotoper Neoblasenanlage
37. 2372P Efficacy of a tailored approach with nivolumab (N) and nivolumab+ipilimumab (N+I) as immuno-therapeutic boost in metastatic urothelial carcinoma (mUC): Final results of TITAN-TCC
38. LBA104 First safety and efficacy results of the TAR-210 erdafitinib (erda) intravesical delivery system in patients (pts) with non–muscle-invasive bladder cancer (NMIBC) with select FGFR alterations (alt)
39. Die Zystektomie im Alter: Komplikationsanalyse unter Anwendung der Clavien-Dindo-Klassifikation
40. Selecting the best candidates for platinum-based adjuvant chemotherapy after radical cystectomy in pN+ bladder cancer patients
41. Functional outcomes and their impact on long-term quality of life after open retropubic radical prostectomy: ID 264
42. Evaluation präoperativer Prädiktoren für einen positiven Resektionsstatus bei radikaler Prostatektomie
43. Einfluss der Operationstechnik (offen/Roboter-assistiert) auf funktionelle Ergebnisse nach radikaler Prostatektomie bei 'high-volume' Operateuren
44. THE IMPACT OF TREATMENT MODALITY ON SURVIVAL IN PATIENTS WITH CLINICAL NODE POSITIVE BLADDER CANCER
45. Corrigendum to ‘EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer—An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees’ [European Urology 77 (2020) 223–250](S0302283819307638)(10.1016/j.eururo.2019.09.035)
46. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees
47. Randomized controlled multicentre study of albumin replacement therapy in septic shock (ARISS): protocol for a randomized controlled trial
48. Défaut d’adoption de l’instillation intravésicale postopératoire précoce de chimiothérapie après néphro-urétérectomie totale
49. Impact of residual microscopial evidence of prostate cancer at second tumor resection on biochemical recurrence after radical prostatectomy
50. Adjuvant chemotherapy is ineffective in patients with bladder cancer and variant histology treated with radical cystectomy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.